Roper to acquire Sunquest Information Systems

Monday, July 30, 2012 02:57 PM

Roper Industries, a provider of engineered products and solutions for global niche markets, has agreed to acquire Sunquest Information Systems, a provider of diagnostic and laboratory software solutions to healthcare providers.

The all cash transaction is valued at $1.4 billion, including $25 million in cash tax benefits. The business will continue as Sunquest, marketing products and services under current brand names.

Roper expects the acquisition of Sunquest to be immediately cash accretive and to generate $140 million or more of EBITDA in 2013, excluding the impact of fair value accounting of Sunquest's deferred revenue. Sunquest is owned by a group of investors resulting from a 2010 recapitalization, led by Huntsman Gay Global Capital, in partnership with Vista Equity Partners, which has owned the company since 2007.

Based in Tucson, Ariz., Sunquest provides a comprehensive suite of clinical and anatomic laboratory software solutions. More than 1,700 hospital laboratories, which provide information that drives the majority of diagnostic decisions, use Sunquest software solutions to integrate data and improve workflow. Sunquest also provides a growing suite of software solutions beyond the hospital laboratory with a focus on point-of-care patient safety and physician outreach.

"Sunquest meets all of Roper's key acquisition criteria and is an ideal fit with both our medical and software platforms," said Brian Jellison, chairman, president and CEO of Roper. "The business is the market leader in software solutions for the critically important healthcare provider laboratory market. We expect Sunquest to benefit in all economic environments from very favorable market forces—an aging population, expansion of anatomic pathology, and the need for reduced healthcare costs and improved quality of care.”

Richard Atkin, president and CEO of Sunquest, added, "As we move forward, we will have the financial and strategic resources necessary to provide enhanced product offerings and expand into new areas.”

Completion of the transaction, which is expected within 30 days, is subject to Hart-Scott-Rodino approval and customary closing conditions.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs